Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors

Background: Patients with anaplastic lymphoma kinase-rearranged (ALK+) NSCLC inevitably acquire resistance to ALK inhibitors. We hypothesized that longitudinal monitoring of cell-free plasma DNA (cfDNA) next generation sequencing (NGS) could predict the response and resistance of TKI therapy in ALK+NSCLC... Conclusions: NGS of cell-free plasma DNA is useful not only for the detection of ALK fusions and resistance mutations but also for assessing prognosis and monitoring the dynamic changes of genomic alterations in ALK+ NSCLC treated with ALK TKI. READ ARTICLE

Journal of Clinical Oncology DOI:10.1200/JCO.2020.38.15_suppl.9603

Authors: Minsuk Kwon, Bo Mi Ku, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

Review PaperKirk SmithMay 25, 2020Longitudinal monitoring, next generation sequencing (NGS), plasma cell-free DNA, ALK, non-small cell lung cancer (NSCLC), tyrosine kinase inhibitors

Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI–Treated Non–Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy

Mutation profiling using liquid biopsy has become a promising approach for monitoring tumor genomic evolution when tissue biopsy is not available. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2019.02.014

Authors: MeijuanDing, Lili Deng, Ruoying Yu, Dan Lu, Yun Bai, Xue Wu, Yang W. Shao, Yu Yang

Case StudyKirk SmithFebruary 27, 2019ALK secondary mutation, EML4-ALK, Longitudinal monitoring, Resistance mutation, Target sequencing